What is Prelude Therapeutics Incorporated's (PRLD) StockRank?

MoatMap's StockRank for Prelude Therapeutics Incorporated (PRLD) is 34/100, with a Sell signal. This is a composite score combining Quality (23), Value (34), and Momentum (69) factor ranks across MoatMap's 19,000+ stock universe.

Does Prelude Therapeutics Incorporated have an economic moat?

Prelude Therapeutics Incorporated (PRLD) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Prelude Therapeutics Incorporated a buy, hold, or sell?

MoatMap's current signal for Prelude Therapeutics Incorporated (PRLD) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated (PRLD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PRLD

SELLREMOVE

Prelude Therapeutics Incorporated · Healthcare · United States · $313M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-95.2%

D/E

0.3x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Prelude Therapeutics is a clinical-stage biotech with no commercialized products or cash flows. This violates our core quality compounder principles, and it does not benefit from the CDMO pricing power cycle as it is a drug developer, not a manufacturer.

COMPANY DESCRIPTION

Prelude Therapeutics Incorporated is a clinical-stage biotechnology company focused on developing small molecule therapies for cancer, particularly targeting key oncology pathways. The company's pipeline includes candidates designed to inhibit specific protein targets involved in tumor growth and progression. Its competitive moat relies on its robust drug discovery platform and the potential of its selective inhibitors to address unmet needs in oncology.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	7M	12M	73.4%
EPS	-2.44	-2.02	-1.68	-1.29	—
Shares	48M	55M	55M	63M	+31.4%
Debt	2M	17M	18M	18M	113.3%
Equity	195M	237M	131M	69M	-29.4%
Op CF	-84M	-107M	-103M	-56M	—
Inv CF	82M	-35M	90M	53M	—
Fin CF	815,000	136M	-120,000	25M	—

PRICE (1M)-5.9%

SMA 50SMA 200

$4.46

RSI (14)

58.1

52W High

$5.54

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-118.4%4.2

ROE

-95.2%8.2

GP/Assets

11.8%29.4

Op. Margin

-309.5%12.1

FCF/Assets

-12.7%24.9

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.29x43.2

Current Ratio

2.03x37.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-4.7x72.5

P/FCF

—N/A

P/B

4.7x25.6

P/S

21.4x16.6

Div Yield

—N/A

Momentum

52W High %

81%75.4

RS 6M

165%98.8

SMA 50/200

1.68x99.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+6%25.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$313M

P/E (Forward)

-4.8x

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRLD are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PRLD	Prelude Therapeutics Incorporated(you)	$313M	34	SELL
FATE	Fate Therapeutics, Inc.	$307M	35	SELL
PALI	Palisade Bio, Inc.	$358M	35	SELL
NAUT	Nautilus Biotechnology, Inc.	$330M	33	SELL
ELDN	Eledon Pharmaceuticals, Inc.	$299M	37	HOLD
ALXO	ALX Oncology Holdings Inc.	$254M	34	SELL
SRZN	Surrozen, Inc.	$304M	39	HOLD
IRD	Opus Genetics, Inc.	$342M	39	HOLD
CDXS	Codexis, Inc.	$250M	32	SELL
XFOR	X4 Pharmaceuticals, Inc.	$390M	38	HOLD

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.2%

Prelude Therapeutics Incorporated (PRLD) — Stock Score Summary

Prelude Therapeutics Incorporated (PRLD) has a MoatMap StockRank of 34/100 based on Quality (23/100), Value (34/100), and Momentum (69/100) factor scores. The current signal is SELL. Prelude Therapeutics is a clinical-stage biotech with no commercialized products or cash flows. This violates our core quality compounder principles, and it does not benefit from the CDMO pricing power cycle as it is a drug developer, not a manufacturer.

Key Financial Metrics

Price	$4.46
Market Cap	$313M
P/E (Forward)	-4.78
Price/Book	4.70
Return on Equity	-95.2%
Return on Invested Capital	-118.4%
Debt/Equity	29.45
Gross Margin	100.0%
Operating Margin	-309.5%
Free Cash Flow	$-18M

Prelude Therapeutics Incorporated operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Prelude Therapeutics Incorporated’s (PRLD) StockRank?: MoatMap’s StockRank for Prelude Therapeutics Incorporated (PRLD) is 34/100, with a Sell signal. It is a composite of Quality (23), Value (34), and Momentum (69) factor ranks across MoatMap’s 19,000+ stock universe.
Does Prelude Therapeutics Incorporated have an economic moat?: Prelude Therapeutics Incorporated (PRLD) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Prelude Therapeutics Incorporated a buy, hold, or sell?: MoatMap’s current signal for Prelude Therapeutics Incorporated (PRLD) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Prelude Therapeutics Incorporated in?: Prelude Therapeutics Incorporated (PRLD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).